TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Low-FODMAP Diet for Functional Abdominal Pain Disorders in Children.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* functional abdominal pain - not otherwise specified (FAP-NOS) or irritable bowel syndrome (IBS) diagnosed according to the Rome IV Criteria,~* baseline average pain intensity at least 30 mm on a 100-mm Visual Analogue Scale,~* feeding via the oral route,~* ability to read and comprehend any employed questionnaires/scales,~* signed informed consent,~* stated availability throughout the study period.~Exclusion Criteria:~* receiving any other intervention/treatment with regard to FAP-NOS or IBS or those who received any other intervention during the last 3 months,~* an organic cause of symptoms or organic gastrointestinal disease,~* chronic illness, receiving medications which affect gastrointestinal motility,~* need for any other dietary management which could make the balancing or compliance with the diet troublesome,~* previously diagnosed carbohydrate intolerance without symptoms of FAPD after implementation of an exclusion diet,~* undernutrition (defined as World Health Organization \[WHO\] growth charts \< -2 SD), decreased growth velocity (sharp decline in growth line), or overweight or obese (\> 1 or \> 2 SD on the WHO growth charts, respectively),~* unintentional weight loss greater or equal to 5% of subject' body weight within the previous 3 months,~* pregnancy,~* eating disorders,~* prior surgery of the gastrointestinal tract (within last 3 months),~* recurrent or unexplained fever,~* developmental disabilities which impair the ability of the child to understand or communicate.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Low-FODMAP diet (Type: EXPERIMENTAL): 37 participants.
- Regular diet (Type: NO_INTERVENTION): 37 participants. The regular diet will reflect the habitual FODMAP intake in a normal diet.~Diets in both groups will be matched in terms of total energy, fat, protein, carbohydrates and dietary fiber with the usual participant's diet.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Epidural Versus Patient-controlled Analgesia for Reduction in Long-term Mortality Following Colorectal Cancer Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA status 1-3~* Age group 40-80 years old~* Undergoing elective surgery for colorectal cancer~Exclusion Criteria:~* All contraindications to epidural analgesia~* Chronic opiate medication/drug abuse~* Allergy to morphine

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Epidural anesthesia and analgesia (Type: EXPERIMENTAL): None
- Patient controlled analgesia (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~• Patient with eosinophilic asthma who completed the treatment period of a double-blind, placebo controlled sc reslizumab study (Study C38072-AS-30025 or C38072-AS-30027)~\~\~ Additional criteria apply, please contact the investigator for more information~Exclusion Criteria:~* Patient has received any reslizumab administration in any previous clinical trial other than Studies C38072-AS-30025 and C38072-AS-30027.~* The patient has any clinically significant, uncontrolled medical condition~* The patient has another confounding underlying lung disorder~* The patient has a known/diagnosed hypereosinophilic syndrome.~* The patient has a diagnosis of malignancy within 5 years of the screening visit, except for treated and cured non-melanoma skin cancers.~* The patient is a pregnant or lactating woman~* The patient is a current smoker (ie, has smoked within the last 6 months before screening) or has a smoking history ≥10 pack-years.~* The patient is currently using any systemic immunosuppressive or immunomodulatory agents other than OCS~* The patient has a history of allergic reaction or hypersensitivity to any component of the study drug.~* The patient has a history of an immunodeficiency disorder including human immunodeficiency virus (HIV).~  * Additional criteria apply, please contact the investigator for more information

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- reslizumab 110 mg (Type: EXPERIMENTAL): Reslizumab was administered as 110 mg subcutaneous (sc) injection in the thigh, abdomen, or upper arm(s) once every 4 weeks for a total of 9 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of a Skin Barrier

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. is at least 18 years of age.~2. has an ileostomy.~3. is at least six weeks postoperative.~4. lives and cares for their stoma independently in the community.~5. currently uses a Dansac Nova or NovaLife 1-piece flat skin barrier.~6. currently uses a drainable pouch.~7. is able to wear a 1-piece flat cut-to-fit 10-55 mm.~8. Has a peristomal skin irritation score of 2 or less.~9. is willing to follow the protocol as demonstrated by signing the informed consent and who in the opinion of the investigator is qualified to participate.~Exclusion Criteria:~1. has a fistula on or near the stoma.~2. has been involved in a study involving stoma care with in the last 30 days.~3. is pregnant or lactating, as determined by interview only.~4. is undergoing chemotherapy, radiation or steroid therapy.~5. has an existing medical condition that would compromise their participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Scheduled for an ERCP at Dartmouth-Hitchcock~2. Age greater than 18 years old~3. Ability to provide written informed consent~Exclusion Criteria:~1. Inability to provide written informed consent~2. ERCP being performed for diagnosis and/or treatment of acute pancreatitis~3. Current ongoing acute pancreatitis~4. Previously documented allergy to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)~5. Contra-indication to NSAID therapy (creatinine level \>1.4 or active peptic ulcer disease), already taking NSAIDs (other than aspirin therapy for cardioprotection)~6. Pregnant or nursing mothers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indomethacin (Type: EXPERIMENTAL): Indomethacin 100 mg Per Rectum (PR) x 1 in peri-procedural period
- Placebo (Type: PLACEBO_COMPARATOR): Placebo suppositories (#2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life for Patients With Chronic Paediatric Onset Inflammatory Bowel Disease (IBD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, between 12 and 24 years old included at the time of the study~* Subject listed in the EPIMAD registry suffering from certain or probable Crohn's disease, or certain or probable ulcerative colitis, or certain or probable ulcerative proctitis~* Disease diagnosed before the age of 17 (pediatric onset disease)~* Patient residing in the area of the EPIMAD register at the time of diagnosis: Nord, Pas-de-Calais, Somme or Seine-Maritime~* Patient not opposing the research~* Patient not having objected to the use of these data for ancillary studies when registering in the EPIMAD register~Exclusion Criteria:~* No exclusion criteria

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 24 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Intravitreal REGN2176-3 in Participants With Neovascular (Wet) Age-Related Macular Degeneration (AMD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Men or women ≥50 years of age~2. Active subfoveal CNV secondary to AMD as evidenced by FA in the study eye, as determined by the reading center, including juxtafoveal lesions that affect the fovea~3. BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye at the screening visit~4. Provide signed informed consent~Key Exclusion Criteria:~1. Any prior treatment with anti-VEGF treatment in the study eye~2. Any prior treatment (ie, systemic or ocular treatment) with PDGF or PDGFR inhibitors~3. Dense fibrotic scar or atrophy in the study eye involving the center of the fovea~4. Presence of retinal pigment epithelial tears or rips involving the macula in the study eye~5. Prior vitrectomy in the study eye~6. Any history of macular hole of stage 2 and above in the study eye~7. Any intraocular or periocular surgery within 3 months of day 1 in the study eye, except lid surgery~8. History of corneal transplant in the study eye~9. Evidence of diabetic retinopathy or diabetic macular edema in either eye~10. Positive serum human chorionic gonadotropin/urine pregnancy test at the screening or baseline visit

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- REGN2176-3 (1 mg: 2 mg) (Type: EXPERIMENTAL): Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
- REGN2176-3 (3 mg: 2 mg) (Type: EXPERIMENTAL): Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
- Intravitreal Aflibercept Injection (IAI) 2 mg (Type: EXPERIMENTAL): IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
- REGN2176-3 (3 mg: 2 mg) to IAI 2 mg (Type: EXPERIMENTAL): Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly with IAI 2 mg up to Week 28, then criteria based re-dosing from Week 28-52.
- IAI 2 mg to REGN2176-3 (3 mg:2 mg) (Type: EXPERIMENTAL): IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly with REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) up to Week 28, then criteria based re-dosing from Week 28-52.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Regenexx™ PL-Disc Versus Steroid Epidurals for Lumbar Radiculopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pain, spasm, or functional disability in the low back and diagnosed as radiculopathy having failed conservative treatment (e.g. NSAIDs, physician initiated physical therapy) for at least 3 months and not longer than 2 years~* Significant functional disability related to pain, lack of strength, or other back or leg symptoms~* Physical examination consistent with lumbar radiculopathy~* Lumbar disc bulge, herniation, and/or Kader grade 2 or greater multifidus atrophy evident on MRI and consistent with physical exam findings~* Is independent, ambulatory, and can comply with all post-operative evaluations and visits~Exclusion Criteria:~* Symptomatic central or foraminal stenosis~* Previous low back surgery~* Prior epidural steroid injection or other low back injection therapy within the past year~* \>50% loss of disc height at the symptomatic level~* Spondylolisthesis~* Inflammatory or auto-immune based pathology (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, polymyalgia, polymyositis, gout pseudogout)~* Quinolone or Statin induced myopathy/tendinopathy~* Severe neurogenic inflammation of the cutaneous nerves~* Condition represents a worker's compensation case~* Currently involved in a health-related litigation procedure~* Is pregnant~* Bleeding disorders~* Currently taking anticoagulant or immunosuppressive medication~* Allergy or intolerance to study medication~* Use of chronic opioid,~* Documented history of drug abuse within six months of treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Regenexx PL-Disc (Type: ACTIVE_COMPARATOR): Injection of Regenexx PL-Disc into the epidural space once a week for two weeks.
- Steroid Epidural (Type: ACTIVE_COMPARATOR): Injection of steroid into the epidural space once a week for two weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Shunt to Trabeculectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All subjects must:~1. Be willing and able to provide written Informed Consent.~2. Be able and willing to follow instructions on the use of post- operative medication and likely to complete the entire course of the study.~3. Be male or female of any race at least 18 years of age.~4. Have medically uncontrolled glaucoma for which they have elected to undergo surgery.~5. Diagnosed with primary open angle glaucoma, pigmentary or pseudoexfoliation glaucoma.~Exclusion Criteria:~No subject may:~1. Have any contraindication to intraocular surgery.~2. Diagnosed with: primary angle closure glaucoma, normal tension glaucoma, secondary glaucoma, neovascular glaucoma.~3. Have any active ocular disease other than glaucoma that would interfere with study parameters (such as: uveitis, ocular infection, or severe dry eye). Subjects with mild chronic blepharitis, age-related macular degeneration and background diabetic retinopathy may be enrolled at the discretion of the investigator.~4. Have laser ALT or SLT within the past 3 months or cataract surgery within the last six months.~5. Require use of ocular NSAID or systemic steroids.~6. Have known allergy or sensitivity to mitomycin C~7. Have corneal abnormalities that would interfere with the ability to obtain an adequate laser flare measurement.~8. Be concurrently enrolled in an investigational drug or device study or participation within the last 30 days in any investigational drug or device study.~9. Be pregnant, nursing, planning a pregnancy, or be of childbearing potential and not using a reliable form of contraception (a woman is considered of childbearing potential unless she is postmenopausal, has had a uterus and/or both ovaries removed, or has had a bilateral tubal ligation).~10. Have a situation or condition that in the investigator's opinion may put the subject at significant risk, may confound the study results, or may interfere significantly with participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Trabeculectomy with Mitomycin C 0.2 mg/cc for 2 minutes
- 2 (Type: ACTIVE_COMPARATOR): Ex-Press mini shunt; Model R50 with mitomycin C 0.2 mg/cc for 2 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Neurostimulation in Temporomandibular Disorders (TMD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18-65 years~* English speaking~* Females with chronic TMD~Exclusion Criteria:~* History of any of the following: Terminal, progressive and /or unstable medical illness; Previous head or neck surgery for neoplasm; current chemotherapy or radiation therapy; facial trauma or orofacial surgery within the last 6 weeks; seizures, history of drug or alcohol abuse; Otologic disorders including chronic vertigo, chronic tinnitus, otitis external, otitis media, mastoiditis and tympanic membrane perforation; Stroke, transient ischemia attacks or Arnold- Chiari malformation; significant cardiac or respiratory disease; epilepsy or neurological disorders such as dementia, brain injury, and brain tumor~* Subjects who score ≥ 31 on the Becks depression inventory (performed at first appointment)~* History of or current destructive nerve therapies, defibrillator, pacemakers, deep brain stimulator, or Implantable nerve stimulators~* Utilization of other alternative or complementary therapies during the study period~* Participation in a clinical trial involving the use of a clinical devise in the last 30 days~* Women who are currently pregnant or nursing.~* Patients who are left handed.~* Current orthodontic treatment.~* Use of an opiate in the 48 hour period preceding the baseline study visit~* The use of anti-histamines 6 hours before, during or immediately after the treatment period~* The use of anti-nausea or anti-vertigo drugs 6 hours before or during the treatment period

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Caloric Vestibular Neurostimulation (Type: EXPERIMENTAL): Subjects received caloric vestibular neurostimulation
- Placebo Arm (Type: PLACEBO_COMPARATOR): Subjects received placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-75 years old (including 18 and 75 years);~2. clinically diagnosed grade 2 or 3 radiation-induced lung injury;~3. the course of radiation-induced lung injury is less than 2 months;~4. ECOG 0-2;~5. the expected survival time is more than 6 months;~6. the functional level of major organs meets the following standards: ANC≥3.0×109/L，PLT≥100×109/L，Hb≥90g/L, TBIL、BUN and Cr≤1.5×ULN， ALT、AST≤2.0×ULN~7. capable of eating solid food upon enrollment;~8. subjects will voluntarily participate in this study and sign the informed consent.~Exclusion Criteria:~1. have a history of chronic bronchial acute attack or severe pulmonary heart disease;~2. pneumonectomy;~3. tumor progression;~4. severe pulmonary infection;~5. creatinine clearance rate \< 30ml/min, severe renal disease or need dialysis;~6. concomitant with other serious diseases: for example, myocardial infarction within 6 months, uncontrolled diabetes, etc., were considered not suitable for the participants in the study;~7. patients with active peptic ulcer;~8. pregnant women and patients with mental illness;~9. participating in clinical trials of other drugs within 3 months;~10. the investigator determined that subject was not suitable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pirfenidone (Type: EXPERIMENTAL): pirfenidone + basic treatment
- Controll (Type: OTHER): with basic treatment and without pirfenidone treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility